



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Martin L. Bryant *et al.*

Serial No.: 09/883,033

Filed: June 15, 2001

Title: 3'-Prodrugs of 2'-Deoxy-β-L-Nucleosides

Assistant Commissioner for Patents
Washington, DC 20231COPY OF PAPERS
ORIGINALLY FILED16,23
#61A
9-11-02
RECEIVED
AUG 30 2002

TECH CENTER 1600/2900

August 16, 2002

AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT


Sir:

In response to the Restriction Requirement mailed on July 16, 2002, please amend the above-identified application as follows.

✓ ✓ ✓ ✓
In the Claims

Please cancel claims 1-155; 157-162 and 164-174. Please add claims 175-241 as follows:

175. (New) A compound of the formula:



or its pharmaceutically acceptable salt thereof, wherein

R² is selected from the group consisting of straight chained, branched or cyclic alkyl, CO-alkyl, CO-aryl, CO-alkoxyalkyl, CO-aryloxyalkyl, CO-substituted aryl, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, amino acid residue, mono, di, or triphosphate, or a phosphate prodrug; and




AMENDMENT AND RESPONSE TO RESTRICTION REQUIREMENT
U.S.S.N. 09/883,033
Filed on June 15, 2001
Attorney Docket No. 06171.105026 (IDX 1005 US)

**COPY OF PAPERS
ORIGINALLY FILED**

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8 (a)

I hereby certify that this Amendment and Response to Restriction Requirement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.


Josephine Young

Date: August 16, 2002